$CLYM News

HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20

Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate

BTIG Maintains Buy on Climb Bio, Raises Price Target to $19

Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE

Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing

Chardan Capital Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $22

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026

Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease

Climb Bio, Inc. Announces $110.0 Million Private Placement

Climb Bio Announces $110M Private Placement Priced At $9.50/Share For ~9.481M Shares

Climb Bio Announces $110M Private Placement Priced At $9.50/Share For ~9.481M Shares

Climb Bio shares are trading higher after Oppenheimer raised its price target on the stock from $10 to $18.

Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $18

FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?

Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway

Mizuho Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $18

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026